November 2-3, 2019
From the event website:
This 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning and role-play exercises. It is the first time a program of this kind has been offered in Montreal.
Psychedelics 101: Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.
Learning Objectives:
- State the historical justifications for psychedelic clinical research
- Describe key theoretical approaches to psychedelic-assisted therapy
- Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients
- Define and differentiate psychedelic integration psychotherapy from integration in peer and shamanic settings
Psychedelics 102: What are psychedelic harm reduction and integration and how can they occur in a clinical setting? This session focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues.
Learning Objectives:
- Identify key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
- Perform basic/initial assessment of clients who report psychedelic use
- Identify contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
- Define and differentiate the role of the therapist in an individual’s psychotherapeutic process
If you have any questions, contact enielson@cfol.org.
For more information, visit the event website.